You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBrimonidine
Accession NumberDB00484  (APRD00034)
TypeSmall Molecule
GroupsApproved
DescriptionBrimonidine is a drug used to treat glaucoma. It acts via decreasing aqueous humor synthesis. [Wikipedia] A topical gel formulation, marketed under the name Mirvaso, was FDA approved on August 2013 for the treatment of rosacea.
Structure
Thumb
Synonyms
5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline
Brimonidina
Brimonidine
Brimonidinum
Bromoxidine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alphaganliquid0.2 %ophthalmicAllergan Inc1997-12-02Not applicableCanada
Alphagan Psolution/ drops1.5 mg/mLophthalmicAllergan, Inc.2001-07-10Not applicableUs
Alphagan Psolution0.15 %ophthalmicAllergan Inc2003-11-05Not applicableCanada
Alphagan Psolution/ drops1.5 mg/mLophthalmicPhysicians Total Care, Inc.2002-10-16Not applicableUs
Alphagan Psolution/ drops1 mg/mLophthalmicAllergan, Inc.2006-01-25Not applicableUs
Alphagan Psolution/ drops1 mg/mLophthalmicPhysicians Total Care, Inc.2013-03-08Not applicableUs
Brimonidinesolution0.2 %ophthalmicPharmascience IncNot applicableNot applicableCanada
Brimonidine Ophthalmicsolution0.2 %ophthalmicPharmel IncNot applicableNot applicableCanada
Brimonidine Psolution0.15 %ophthalmicAa Pharma Inc2008-07-15Not applicableCanada
Brimonidine Tartratesolution1.5 mg/mLophthalmicSandoz Inc2010-10-02Not applicableUs
Brimonidine Tartratesolution1.5 mg/mLophthalmicPhysicians Total Care, Inc.2009-12-22Not applicableUs
Brimonidine Tartratesolution/ drops2 mg/mLophthalmicPacific Pharma, Inc.2003-04-10Not applicableUs
Brimonidine Tartrate Ophthalmic Solution 0.2%solution0.2 %ophthalmicAlcon Canada IncNot applicableNot applicableCanada
Dom-brimonidinesolution0.2 %ophthalmicDominion PharmacalNot applicableNot applicableCanada
Jamp-brimonidinesolution0.2 %ophthalmicJamp Pharma CorporationNot applicableNot applicableCanada
MirvasoGel3 mg/gCutaneous useGalderma International2014-02-21Not applicableEu
MirvasoGel3 mg/gCutaneous useGalderma International2014-02-21Not applicableEu
MirvasoGel3 mg/gCutaneous useGalderma International2014-02-21Not applicableEu
MirvasoGel3 mg/gCutaneous useGalderma International2014-02-21Not applicableEu
Mirvasogel5 mg/gtopicalGalderma Laboratories, L.P.2013-08-23Not applicableUs
MirvasoGel3 mg/gCutaneous useGalderma International2014-02-21Not applicableEu
MirvasoGel3 mg/gCutaneous use 1Galderma International2014-02-21Not applicableEu
Onrelteagel0.33 %topicalGalderma Canada Inc2014-03-24Not applicableCanada
PMS-brimonidinesolution0.2 %ophthalmicPharmascience Inc2002-08-13Not applicableCanada
Ratio-brimonidinesolution0.2 %ophthalmicTeva Canada Limited2002-07-10Not applicableCanada
Sandoz Brimonidinesolution0.2 %ophthalmicSandoz Canada Incorporated2008-02-08Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-brimonidinesolution0.2 %ophthalmicApotex Inc2005-06-02Not applicableCanada
Brimonidinesolution/ drops2 mg/mLophthalmicAkorn, Inc.2006-09-07Not applicableUs
Brimonidine Tartratesolution/ drops2 mg/mLophthalmicSTAT Rx USA LLC2003-05-28Not applicableUs
Brimonidine Tartratesolution/ drops2 mg/mLophthalmicREMEDYREPACK INC.2013-06-24Not applicableUs
Brimonidine Tartratesolution/ drops2 mg/mLophthalmicPhysicians Total Care, Inc.2011-07-25Not applicableUs
Brimonidine Tartratesolution/ drops2 mg/mLophthalmicRegimed Medical2016-01-05Not applicableUs
Brimonidine Tartratesolution/ drops2 mg/mLophthalmicBausch & Lomb Incorporated2003-05-28Not applicableUs
Brimonidine Tartratesolution2 mg/mLophthalmicSandoz Inc2003-09-17Not applicableUs
Brimonidine Tartratesolution/ drops2 mg/mgophthalmicOsmotica Pharmaceutical Corp.2015-01-01Not applicableUs
Brimonidine Tartrate Ophthalmic Solution, 0.2%solution/ drops2 mg/mLophthalmicWestminster Pharmaceuticals, Llc2015-09-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Apo-brimonidine-timopApotex Inc
CombiganAllergan, Inc.
SimbrinzaAlcon Laboratories, Inc.
Salts
Name/CASStructureProperties
Brimonidine Tartrate
70359-46-5
Thumb
  • InChI Key: QZHBYNSSDLTCRG-LREBCSMRSA-N
  • Monoisotopic Mass: 441.028395916
  • Average Mass: 442.221
DBSALT000195
Categories
UNIIE6GNX3HHTE
CAS number59803-98-4
WeightAverage: 292.135
Monoisotopic: 291.011957992
Chemical FormulaC11H10BrN5
InChI KeyInChIKey=XYLJNLCSTIOKRM-UHFFFAOYSA-N
InChI
InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
IUPAC Name
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
SMILES
BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinoxalines. These are compounds containing a quinoxaline moiety, a bicyclic heterocycle made up of a benzene ring fused to a pyrazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassQuinoxalines
Direct ParentQuinoxalines
Alternative Parents
Substituents
  • Quinoxaline
  • 2-bromoaniline
  • Benzenoid
  • Pyrazine
  • Aryl halide
  • Aryl bromide
  • Heteroaromatic compound
  • 2-imidazoline
  • Guanidine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationThe ophthalmic solution is indicated for patients with open-angle glaucoma or ocular hypertension to lower intraocular pressure. The topical gel is indicated for the treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years or older.
PharmacodynamicsBrimonidine significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. It lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.
Mechanism of actionBrimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. The topical gel reduces erythema through direct vasocontriction.
Related Articles
AbsorptionMinimal systemic absorption occurs after ocular insertion. When the topical gel was applied to adult patients with facial erythema associated with rosacea, the plasma maximum concentration (Cmax) and area under the concentration-time curve (AUC) were 46 ± 62 pg/mL and 417 ± 264 pg.hr/mL, respectively. These values were reached on Day 15 of treatment.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Metabolized primarily by the liver.

SubstrateEnzymesProduct
Brimonidine
2-oxobrimonidineDetails
Brimonidine
3-oxobrimonidine Details
Route of eliminationUrinary excretion is the major route of elimination of the drug and its metabolites.
Half life2 hours [ophthalmic solution]
ClearanceNot Available
ToxicityOral LD50 is 50 mg/kg in mice and 100 mg/kg in rats. Common adverse reactions of the topical gel formulation include erythema, flushing, skin burning sensation, and contact dermatitis.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.978
Blood Brain Barrier+0.717
Caco-2 permeable+0.5435
P-glycoprotein substrateSubstrate0.7017
P-glycoprotein inhibitor INon-inhibitor0.5688
P-glycoprotein inhibitor IIInhibitor0.5951
Renal organic cation transporterInhibitor0.8266
CYP450 2C9 substrateNon-substrate0.8403
CYP450 2D6 substrateNon-substrate0.7533
CYP450 3A4 substrateNon-substrate0.5617
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.6898
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7044
Ames testNon AMES toxic0.8222
CarcinogenicityNon-carcinogens0.9446
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0196 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8093
hERG inhibition (predictor II)Non-inhibitor0.6711
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Allergan inc
  • Allergan
  • Akorn inc
  • Alcon inc
  • Alcon research ltd
  • Bausch and lomb pharmaceuticals inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Allergan, Inc
Packagers
Dosage forms
FormRouteStrength
Liquidophthalmic0.2 %
Solutionophthalmic0.15 %
Solution/ dropsophthalmic1 mg/mL
Solution/ dropsophthalmic1.5 mg/mL
Solutionophthalmic1.5 mg/mL
Solutionophthalmic2 mg/mL
Solution/ dropsophthalmic2 mg/mg
Solution/ dropsophthalmic2 mg/mL
Solutionophthalmic
Solution/ dropsophthalmic
GelCutaneous use3 mg/g
GelCutaneous use 13 mg/g
Geltopical5 mg/g
Geltopical0.33 %
Solutionophthalmic0.2 %
Suspensionophthalmic
Suspension/ dropsophthalmic
Prices
Unit descriptionCostUnit
Alphagan P 15ml Bottle .15% 15ml Bottle228.5USD bottle
Brimonidine Tartrate 0.15% Solution 15ml Bottle218.5USD bottle
Alphagan P 0.1% Solution 15ml Bottle208.94USD bottle
Alphagan P 10ml Bottle .15% 10ml Bottle152.32USD bottle
Brimonidine Tartrate 0.15% Solution 10ml Bottle145.65USD bottle
Alphagan P 0.1% Solution 10ml Bottle143.97USD bottle
Alphagan P 5ml Bottle .15% 5ml Bottle79.52USD bottle
Brimonidine Tartrate 0.15% Solution 5ml Bottle72.85USD bottle
Brimonidine Tartrate 0.2% Solution 10ml Bottle67.85USD bottle
Brimonidine Tartrate 0.2% Solution 15ml Bottle56.88USD bottle
Brimonidine Tartrate 0.2% Solution 5ml Bottle33.96USD bottle
Brimonidine tartrate 0.15% drp29.82USD ml
Alphagan p 0.15% eye drops14.65USD ml
Alphagan p 0.1% drops13.85USD ml
Brimonidine 0.2% eye drop6.53USD ml
Alphagan 0.2 % Solution3.72USD ml
Apo-Brimonidine 0.2 % Solution2.08USD ml
Pms-Brimonidine 0.2 % Solution2.08USD ml
Ratio-Brimonidine 0.2 % Solution2.08USD ml
Sandoz Brimonidine 0.2 % Solution2.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2173974 No2006-05-022014-09-19Canada
CA2225626 No2002-09-032016-06-17Canada
US5424078 No1995-06-132012-06-13Us
US6316441 No1999-12-072019-12-07Us
US6562873 Yes2002-01-102022-01-10Us
US6627210 Yes2002-01-182022-01-18Us
US6641834 Yes2002-01-282022-01-28Us
US6673337 Yes2002-01-262022-01-26Us
US7030149 No2002-04-192022-04-19Us
US7265117 No2005-08-192025-08-19Us
US7320976 No2002-04-192022-04-19Us
US7323463 No2003-01-192023-01-19Us
US7439241 No2005-08-252025-08-25Us
US7642258 No2002-04-192022-04-19Us
US8053427 No2011-06-132031-06-13Us
US8133890 No2002-04-192022-04-19Us
US8163725 No2011-06-132031-06-13Us
US8231885 No2005-05-242025-05-24Us
US8354409 No2002-04-192022-04-19Us
US8410102 No2005-05-242025-05-24Us
US8426410 No2005-05-242025-05-24Us
US8513247 No2011-03-252031-03-25Us
US8513249 No2011-03-252031-03-25Us
US8748425 No2002-04-192022-04-19Us
US8858961 Yes2004-03-022024-03-02Us
US8859551 No2004-05-252024-05-25Us
US9044484 No2010-10-302030-10-30Us
US9295641 No2001-07-102021-07-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point207.5 °CNot Available
water solubilitySoluble (1.5 mg/mL)Not Available
logP1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.154 mg/mLALOGPS
logP1.27ALOGPS
logP1.37ChemAxon
logS-3.3ALOGPS
pKa (Strongest Basic)8.32ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.2 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity68.49 m3·mol-1ChemAxon
Polarizability25.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesD11AX21S01EA05
AHFS Codes
  • 52:92.00
PDB EntriesNot Available
FDA labelDownload (517 KB)
MSDSDownload (20.9 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Brimonidine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Brimonidine.
AcebutololAcebutolol may increase the hypotensive activities of Brimonidine.
AcebutololBrimonidine may increase the antihypertensive activities of Acebutolol.
AcepromazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Brimonidine.
AceprometazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Brimonidine.
AcetazolamideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Acetazolamide.
adipiplonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of adipiplon.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Brimonidine.
AgomelatineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Brimonidine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Brimonidine.
AlfaxaloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Brimonidine.
AlfentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Brimonidine.
AlfuzosinAlfuzosin may increase the hypotensive activities of Brimonidine.
AliskirenAliskiren may increase the hypotensive activities of Brimonidine.
AliskirenBrimonidine may increase the antihypertensive activities of Aliskiren.
AlphacetylmethadolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Brimonidine.
AlprazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Brimonidine.
AlprenololAlprenolol may increase the hypotensive activities of Brimonidine.
AlprenololBrimonidine may increase the antihypertensive activities of Alprenolol.
AmbrisentanAmbrisentan may increase the hypotensive activities of Brimonidine.
AmbrisentanBrimonidine may increase the antihypertensive activities of Ambrisentan.
AmifostineBrimonidine may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Amiloride.
AmineptineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Amineptine.
AmisulprideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Brimonidine.
AmitriptylineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
AmitriptylineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Amitriptyline.
AmlodipineAmlodipine may increase the hypotensive activities of Brimonidine.
AmlodipineBrimonidine may increase the antihypertensive activities of Amlodipine.
AmobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
AmobarbitalAmobarbital may increase the hypotensive activities of Brimonidine.
AmoxapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Brimonidine.
AmperozideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Brimonidine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Brimonidine is combined with Amyl Nitrite.
ApraclonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Apraclonidine.
AripiprazoleAripiprazole may increase the hypotensive activities of Brimonidine.
AripiprazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
ArotinololBrimonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.
ArticaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Articaine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Brimonidine.
AsenapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Asenapine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Brimonidine.
AtenololAtenolol may increase the hypotensive activities of Brimonidine.
AtenololBrimonidine may increase the antihypertensive activities of Atenolol.
AzaperoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Brimonidine.
AzelastineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Brimonidine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Azilsartan medoxomil.
BaclofenBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Baclofen.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Brimonidine.
BarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Barbital.
BarbitalBarbital may increase the hypotensive activities of Brimonidine.
BefunololBrimonidine may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenazeprilBenazepril may increase the hypotensive activities of Brimonidine.
BenazeprilBrimonidine may increase the antihypertensive activities of Benazepril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Brimonidine.
BendroflumethiazideBrimonidine may increase the antihypertensive activities of Bendroflumethiazide.
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Brimonidine.
BenzocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Brimonidine.
Benzyl alcoholBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Brimonidine.
BepridilBepridil may increase the hypotensive activities of Brimonidine.
BepridilBrimonidine may increase the antihypertensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Brimonidine.
BetaxololBrimonidine may increase the antihypertensive activities of Betaxolol.
BethanidineBethanidine may increase the hypotensive activities of Brimonidine.
BethanidineBrimonidine may increase the antihypertensive activities of Bethanidine.
BevantololBrimonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BimatoprostBimatoprost may increase the hypotensive activities of Brimonidine.
BimatoprostBrimonidine may increase the antihypertensive activities of Bimatoprost.
BisoprololBisoprolol may increase the hypotensive activities of Brimonidine.
BisoprololBrimonidine may increase the antihypertensive activities of Bisoprolol.
BopindololBrimonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BosentanBosentan may increase the hypotensive activities of Brimonidine.
BosentanBrimonidine may increase the antihypertensive activities of Bosentan.
BretyliumBretylium may increase the hypotensive activities of Brimonidine.
BretyliumBrimonidine may increase the antihypertensive activities of Bretylium.
BrexpiprazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Brimonidine.
BromazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brimonidine.
BrompheniramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Brimonidine.
BrotizolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Brimonidine.
BufuralolBrimonidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BumetanideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Bumetanide.
BupivacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brimonidine.
BupranololBupranolol may increase the hypotensive activities of Brimonidine.
BupranololBrimonidine may increase the antihypertensive activities of Bupranolol.
BuprenorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Brimonidine.
BuspironeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Brimonidine.
ButabarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brimonidine.
ButacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butacaine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Brimonidine.
ButalbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butalbital.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Brimonidine.
ButambenBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butamben.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Brimonidine.
ButethalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butethal.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Brimonidine.
ButorphanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brimonidine.
CanagliflozinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Brimonidine.
CandesartanBrimonidine may increase the antihypertensive activities of Candesartan.
CandoxatrilCandoxatril may increase the hypotensive activities of Brimonidine.
CandoxatrilBrimonidine may increase the antihypertensive activities of Candoxatril.
CaptoprilCaptopril may increase the hypotensive activities of Brimonidine.
CaptoprilBrimonidine may increase the antihypertensive activities of Captopril.
CarbamazepineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Brimonidine.
CarbinoxamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Brimonidine.
CarfentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Brimonidine.
CarisoprodolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brimonidine.
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Brimonidine.
CarteololCarteolol may increase the hypotensive activities of Brimonidine.
CarteololBrimonidine may increase the antihypertensive activities of Carteolol.
CarvedilolCarvedilol may increase the hypotensive activities of Brimonidine.
CarvedilolBrimonidine may increase the antihypertensive activities of Carvedilol.
CeliprololCeliprolol may increase the hypotensive activities of Brimonidine.
CeliprololBrimonidine may increase the antihypertensive activities of Celiprolol.
CetirizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Brimonidine.
Chloral hydrateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Brimonidine.
ChlordiazepoxideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Brimonidine.
ChlormezanoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Brimonidine.
ChloroprocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Brimonidine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Brimonidine.
ChlorothiazideBrimonidine may increase the antihypertensive activities of Chlorothiazide.
ChlorphenamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brimonidine.
ChlorpromazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Brimonidine.
ChlorprothixeneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brimonidine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Brimonidine.
ChlorthalidoneBrimonidine may increase the antihypertensive activities of Chlorthalidone.
ChlorzoxazoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Brimonidine.
CilazaprilCilazapril may increase the hypotensive activities of Brimonidine.
CilazaprilBrimonidine may increase the antihypertensive activities of Cilazapril.
CinchocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Brimonidine.
CitalopramThe risk or severity of adverse effects can be increased when Brimonidine is combined with Citalopram.
ClemastineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Brimonidine.
ClevidipineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Clevidipine.
ClidiniumBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Brimonidine.
ClobazamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Brimonidine.
clomethiazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Brimonidine.
ClomipramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
ClomipramineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Clomipramine.
ClonazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Brimonidine.
ClonidineClonidine may increase the hypotensive activities of Brimonidine.
ClonidineBrimonidine may increase the antihypertensive activities of Clonidine.
ClorazepateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brimonidine.
ClozapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Brimonidine.
CocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Brimonidine.
CodeineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Brimonidine.
CryptenamineCryptenamine may increase the hypotensive activities of Brimonidine.
CryptenamineBrimonidine may increase the antihypertensive activities of Cryptenamine.
CyclizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Brimonidine.
CyclobenzaprineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
CyclobenzaprineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Cyclobenzaprine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Brimonidine.
CyclothiazideBrimonidine may increase the antihypertensive activities of Cyclothiazide.
CyproheptadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brimonidine.
DantroleneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Brimonidine.
DapagliflozinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dapagliflozin.
DapiprazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brimonidine.
DapoxetineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dapoxetine.
DebrisoquinDebrisoquin may increase the hypotensive activities of Brimonidine.
DebrisoquinBrimonidine may increase the antihypertensive activities of Debrisoquin.
deramciclaneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of deramciclane.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Brimonidine.
DeserpidineDeserpidine may increase the hypotensive activities of Brimonidine.
DeserpidineBrimonidine may increase the antihypertensive activities of Deserpidine.
DesfluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Brimonidine.
DesipramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
DesipramineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Desipramine.
DesloratadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Brimonidine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Brimonidine.
DetomidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Detomidine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Brimonidine.
DexbrompheniramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brimonidine.
DexmedetomidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Brimonidine.
DextromoramideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Brimonidine.
DextropropoxypheneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brimonidine.
DezocineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Brimonidine.
DiazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Brimonidine.
DiazoxideDiazoxide may increase the hypotensive activities of Brimonidine.
DiazoxideBrimonidine may increase the antihypertensive activities of Diazoxide.
DiclofenamideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Diclofenamide.
DifenoxinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Brimonidine.
DigoxinBrimonidine may increase the bradycardic activities of Digoxin.
DihydrocodeineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brimonidine.
DihydroetorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brimonidine.
DihydromorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brimonidine.
DiltiazemDiltiazem may increase the hypotensive activities of Brimonidine.
DiltiazemBrimonidine may increase the antihypertensive activities of Diltiazem.
DimenhydrinateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Brimonidine.
DinutuximabThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dinutuximab.
DiphenhydramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Brimonidine.
DiphenoxylateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brimonidine.
DipyridamoleThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dipyridamole.
DoramectinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Doramectin.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Brimonidine.
DorzolamideDorzolamide may increase the hypotensive activities of Brimonidine.
DorzolamideBrimonidine may increase the antihypertensive activities of Dorzolamide.
DosulepinThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Dosulepin.
DoxazosinDoxazosin may increase the hypotensive activities of Brimonidine.
DoxazosinBrimonidine may increase the antihypertensive activities of Doxazosin.
DoxepinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DoxepinThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.
DPDPEBrimonidine may increase the central nervous system depressant (CNS depressant) activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Brimonidine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.
DroperidolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Brimonidine.
DrotebanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Brimonidine.
DuloxetineBrimonidine may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineDuloxetine may decrease the antihypertensive activities of Brimonidine.
DyclonineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brimonidine.
EcgonineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Brimonidine.
ECGONINE METHYL ESTERBrimonidine may increase the central nervous system depressant (CNS depressant) activities of ECGONINE METHYL ESTER.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Brimonidine.
EfavirenzBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Brimonidine.
EfonidipineEfonidipine may increase the hypotensive activities of Brimonidine.
EfonidipineBrimonidine may increase the antihypertensive activities of Efonidipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Brimonidine.
EnalaprilBrimonidine may increase the antihypertensive activities of Enalapril.
EnalaprilatEnalaprilat may increase the hypotensive activities of Brimonidine.
EnalaprilatBrimonidine may increase the antihypertensive activities of Enalaprilat.
EnfluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Enflurane.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Brimonidine.
EntacaponeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Brimonidine.
EplerenoneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Eplerenone.
EpoprostenolEpoprostenol may increase the hypotensive activities of Brimonidine.
EpoprostenolBrimonidine may increase the antihypertensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Brimonidine.
EprosartanBrimonidine may increase the antihypertensive activities of Eprosartan.
EscitalopramThe risk or severity of adverse effects can be increased when Brimonidine is combined with Escitalopram.
EsmirtazapineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Esmirtazapine.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Brimonidine.
EstazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Brimonidine.
EszopicloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brimonidine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Brimonidine is combined with Etacrynic acid.
EthanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Brimonidine.
EthchlorvynolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brimonidine.
EthosuximideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brimonidine.
EthotoinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Brimonidine.
Ethyl carbamateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brimonidine.
Ethyl loflazepateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Brimonidine.
EthylmorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brimonidine.
EtidocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Brimonidine.
EtifoxineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Brimonidine.
EtizolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etizolam.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Brimonidine.
EtomidateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Brimonidine.
EtoperidoneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Etoperidone.
EtorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Brimonidine.
EzogabineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Brimonidine.
FelbamateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Brimonidine.
FelodipineFelodipine may increase the hypotensive activities of Brimonidine.
FelodipineBrimonidine may increase the antihypertensive activities of Felodipine.
FencamfamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Brimonidine.
FenfluramineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fenfluramine.
FenoldopamFenoldopam may increase the hypotensive activities of Brimonidine.
FenoldopamBrimonidine may increase the antihypertensive activities of Fenoldopam.
FentanylBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brimonidine.
FexofenadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Brimonidine.
FlibanserinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Brimonidine.
FludiazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Brimonidine.
FlunarizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Brimonidine.
FlunitrazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Brimonidine.
FluoxetineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fluoxetine.
FlupentixolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brimonidine.
FluphenazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brimonidine.
FlurazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brimonidine.
FluspirileneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brimonidine.
Fluticasone PropionateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Brimonidine.
FluvoxamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Brimonidine.
FosinoprilFosinopril may increase the hypotensive activities of Brimonidine.
FosinoprilBrimonidine may increase the antihypertensive activities of Fosinopril.
FosphenytoinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Brimonidine.
FospropofolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Brimonidine.
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Brimonidine.
FurosemideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Furosemide.
GabapentinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Brimonidine.
gabapentin enacarbilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Brimonidine.
Gamma Hydroxybutyric AcidBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Brimonidine.
GlutethimideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Brimonidine.
GuanabenzGuanabenz may increase the hypotensive activities of Brimonidine.
GuanabenzBrimonidine may increase the antihypertensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Brimonidine.
GuanadrelBrimonidine may increase the antihypertensive activities of Guanadrel.
GuanethidineGuanethidine may increase the hypotensive activities of Brimonidine.
GuanethidineBrimonidine may increase the antihypertensive activities of Guanethidine.
GuanfacineGuanfacine may increase the hypotensive activities of Brimonidine.
GuanfacineBrimonidine may increase the antihypertensive activities of Guanfacine.
HalazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Halazepam.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Brimonidine.
HaloperidolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Brimonidine.
HalothaneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Halothane.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Brimonidine.
HeroinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Brimonidine.
HexamethoniumHexamethonium may increase the hypotensive activities of Brimonidine.
HexamethoniumBrimonidine may increase the antihypertensive activities of Hexamethonium.
HexobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.
HexobarbitalHexobarbital may increase the hypotensive activities of Brimonidine.
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Brimonidine.
HydralazineHydralazine may increase the hypotensive activities of Brimonidine.
HydralazineBrimonidine may increase the antihypertensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Brimonidine.
HydrochlorothiazideBrimonidine may increase the antihypertensive activities of Hydrochlorothiazide.
HydrocodoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Brimonidine.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Brimonidine.
HydroflumethiazideBrimonidine may increase the antihypertensive activities of Hydroflumethiazide.
HydromorphoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brimonidine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.
IloperidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Brimonidine.
IloprostIloprost may increase the hypotensive activities of Brimonidine.
ImipramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
ImipramineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Indalpine.
IndapamideIndapamide may increase the hypotensive activities of Brimonidine.
IndapamideBrimonidine may increase the antihypertensive activities of Indapamide.
IndenololIndenolol may increase the hypotensive activities of Brimonidine.
IndenololBrimonidine may increase the antihypertensive activities of Indenolol.
IndoraminIndoramin may increase the hypotensive activities of Brimonidine.
IndoraminBrimonidine may increase the antihypertensive activities of Indoramin.
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Brimonidine.
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Brimonidine.
IrbesartanIrbesartan may increase the hypotensive activities of Brimonidine.
IrbesartanBrimonidine may increase the antihypertensive activities of Irbesartan.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Brimonidine.
IsofluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Brimonidine.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Brimonidine.
IsradipineBrimonidine may increase the antihypertensive activities of Isradipine.
KetamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Brimonidine.
KetazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Brimonidine.
KetobemidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brimonidine.
LabetalolLabetalol may increase the hypotensive activities of Brimonidine.
LabetalolBrimonidine may increase the antihypertensive activities of Labetalol.
LacidipineLacidipine may increase the hypotensive activities of Brimonidine.
LacidipineBrimonidine may increase the antihypertensive activities of Lacidipine.
LamotrigineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brimonidine.
LatanoprostLatanoprost may increase the hypotensive activities of Brimonidine.
LatanoprostBrimonidine may increase the antihypertensive activities of Latanoprost.
LercanidipineLercanidipine may increase the hypotensive activities of Brimonidine.
LercanidipineBrimonidine may increase the antihypertensive activities of Lercanidipine.
LevetiracetamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Brimonidine.
LevobunololThe risk or severity of adverse effects can be increased when Brimonidine is combined with Levobunolol.
LevobupivacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Brimonidine.
LevocabastineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Brimonidine.
LevocetirizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Brimonidine.
LevodopaBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levodopa.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Brimonidine.
Levomethadyl AcetateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brimonidine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Brimonidine is combined with Levomilnacipran.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Brimonidine.
LevorphanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brimonidine.
LidocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Brimonidine.
LisinoprilLisinopril may increase the hypotensive activities of Brimonidine.
LisinoprilBrimonidine may increase the antihypertensive activities of Lisinopril.
LithiumBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lithium.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Brimonidine.
LofentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Brimonidine.
LofexidineLofexidine may increase the hypotensive activities of Brimonidine.
LofexidineBrimonidine may increase the antihypertensive activities of Lofexidine.
LoratadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Brimonidine.
LorazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Brimonidine.
LosartanLosartan may increase the hypotensive activities of Brimonidine.
LosartanBrimonidine may increase the antihypertensive activities of Losartan.
LoxapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Brimonidine.
Lu AA21004Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Brimonidine.
LurasidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brimonidine.
MacitentanMacitentan may increase the hypotensive activities of Brimonidine.
MacitentanBrimonidine may increase the antihypertensive activities of Macitentan.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.
ManidipineManidipine may increase the hypotensive activities of Brimonidine.
ManidipineBrimonidine may increase the antihypertensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Brimonidine is combined with Mannitol.
MaprotilineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Brimonidine.
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Brimonidine.
MecamylamineMecamylamine may increase the hypotensive activities of Brimonidine.
MecamylamineBrimonidine may increase the antihypertensive activities of Mecamylamine.
MeclizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Meclizine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Brimonidine.
MedetomidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Brimonidine.
MelatoninBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Melatonin.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Brimonidine.
MelperoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Melperone.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Brimonidine.
MepivacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brimonidine.
MeprobamateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brimonidine.
MesoridazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brimonidine.
MetaxaloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brimonidine.
MethadoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Brimonidine.
Methadyl AcetateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Brimonidine.
MethapyrileneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Brimonidine.
MethaqualoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Brimonidine.
MethazolamideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Methazolamide.
MethocarbamolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brimonidine.
MethohexitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
MethohexitalMethohexital may increase the hypotensive activities of Brimonidine.
MethotrimeprazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Brimonidine.
MethoxyfluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brimonidine.
MethsuximideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Brimonidine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Brimonidine.
MethyldopaMethyldopa may increase the hypotensive activities of Brimonidine.
MethyldopaBrimonidine may increase the antihypertensive activities of Methyldopa.
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Brimonidine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Brimonidine.
MethylphenobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Brimonidine.
MetipranololMetipranolol may increase the hypotensive activities of Brimonidine.
MetipranololBrimonidine may increase the antihypertensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Brimonidine.
MetolazoneBrimonidine may increase the antihypertensive activities of Metolazone.
MetoprololMetoprolol may increase the hypotensive activities of Brimonidine.
MetoprololBrimonidine may increase the antihypertensive activities of Metoprolol.
MetyrosineBrimonidine may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Mianserin.
MibefradilMibefradil may increase the hypotensive activities of Brimonidine.
MibefradilBrimonidine may increase the antihypertensive activities of Mibefradil.
MidazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Brimonidine.
MilnacipranThe risk or severity of adverse effects can be increased when Brimonidine is combined with Milnacipran.
MilnacipranMilnacipran may decrease the antihypertensive activities of Brimonidine.
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Brimonidine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.
MinoxidilMinoxidil may increase the hypotensive activities of Brimonidine.
MinoxidilBrimonidine may increase the antihypertensive activities of Minoxidil.
MirtazapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Brimonidine.
MoexiprilMoexipril may increase the hypotensive activities of Brimonidine.
MoexiprilBrimonidine may increase the antihypertensive activities of Moexipril.
MolindoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Molindone.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Brimonidine.
MolsidomineMolsidomine may increase the hypotensive activities of Brimonidine.
MorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Brimonidine.
MoxonidineMoxonidine may increase the hypotensive activities of Brimonidine.
MoxonidineBrimonidine may increase the antihypertensive activities of Moxonidine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.
NadololNadolol may increase the hypotensive activities of Brimonidine.
NadololBrimonidine may increase the antihypertensive activities of Nadolol.
NalbuphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brimonidine.
NebivololNebivolol may increase the hypotensive activities of Brimonidine.
NebivololBrimonidine may increase the antihypertensive activities of Nebivolol.
NesiritideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nesiritide.
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Brimonidine.
NicardipineNicardipine may increase the hypotensive activities of Brimonidine.
NicardipineBrimonidine may increase the antihypertensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Brimonidine.
NicorandilBrimonidine may increase the antihypertensive activities of Nicorandil.
NifedipineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nifedipine.
NiguldipineNiguldipine may increase the hypotensive activities of Brimonidine.
NiguldipineBrimonidine may increase the antihypertensive activities of Niguldipine.
NilvadipineNilvadipine may increase the hypotensive activities of Brimonidine.
NilvadipineBrimonidine may increase the antihypertensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Brimonidine.
NimodipineBrimonidine may increase the antihypertensive activities of Nimodipine.
NisoldipineNisoldipine may increase the hypotensive activities of Brimonidine.
NisoldipineBrimonidine may increase the antihypertensive activities of Nisoldipine.
NitrazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Brimonidine.
NitrendipineNitrendipine may increase the hypotensive activities of Brimonidine.
NitrendipineBrimonidine may increase the antihypertensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Brimonidine.
NitroprussideBrimonidine may increase the antihypertensive activities of Nitroprusside.
Nitrous oxideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Brimonidine.
NormethadoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Brimonidine.
NortriptylineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
NortriptylineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Nortriptyline.
ObinutuzumabBrimonidine may increase the hypotensive activities of Obinutuzumab.
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Brimonidine.
OlanzapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Brimonidine.
OlmesartanOlmesartan may increase the hypotensive activities of Brimonidine.
OlmesartanBrimonidine may increase the antihypertensive activities of Olmesartan.
OlopatadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Brimonidine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Brimonidine.
OmapatrilatBrimonidine may increase the antihypertensive activities of Omapatrilat.
OndansetronBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Brimonidine.
OpiumBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Brimonidine.
OrphenadrineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Brimonidine.
OsanetantBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Brimonidine.
OxazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Brimonidine.
OxprenololOxprenolol may increase the hypotensive activities of Brimonidine.
OxprenololBrimonidine may increase the antihypertensive activities of Oxprenolol.
OxybuprocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Brimonidine.
OxycodoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brimonidine.
OxymorphoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brimonidine.
PaliperidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brimonidine.
PapaverineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Papaverine.
ParaldehydeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Brimonidine.
PargylineBrimonidine may increase the antihypertensive activities of Pargyline.
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Brimonidine.
ParoxetineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Paroxetine.
PenbutololPenbutolol may increase the hypotensive activities of Brimonidine.
PenbutololBrimonidine may increase the antihypertensive activities of Penbutolol.
PentazocineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brimonidine.
PentobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
PentobarbitalPentobarbital may increase the hypotensive activities of Brimonidine.
PentoliniumPentolinium may increase the hypotensive activities of Brimonidine.
PentoliniumBrimonidine may increase the antihypertensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Brimonidine.
PerampanelBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Brimonidine.
PerindoprilPerindopril may increase the hypotensive activities of Brimonidine.
PerindoprilBrimonidine may increase the antihypertensive activities of Perindopril.
PerospironeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perospirone.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Brimonidine.
PerphenazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brimonidine.
PethidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Brimonidine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Brimonidine.
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Brimonidine.
PhenobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Brimonidine.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Brimonidine.
PhenoxybenzamineBrimonidine may increase the antihypertensive activities of Phenoxybenzamine.
PhenoxyethanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Brimonidine.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Brimonidine.
PhentolaminePhentolamine may increase the hypotensive activities of Brimonidine.
PhentolamineBrimonidine may increase the antihypertensive activities of Phentolamine.
PhenytoinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Brimonidine.
PimozideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Brimonidine.
PinacidilPinacidil may increase the hypotensive activities of Brimonidine.
PinacidilBrimonidine may increase the antihypertensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Brimonidine.
PindololBrimonidine may increase the antihypertensive activities of Pindolol.
PipamperoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Brimonidine.
PipotiazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Brimonidine.
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Brimonidine.
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Brimonidine.
PizotifenBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Brimonidine.
PolythiazidePolythiazide may increase the hypotensive activities of Brimonidine.
PolythiazideBrimonidine may increase the antihypertensive activities of Polythiazide.
PomalidomideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Brimonidine.
PractololBrimonidine may increase the atrioventricular blocking (AV block) activities of Practolol.
PramipexoleBrimonidine may increase the sedative activities of Pramipexole.
PramocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Brimonidine.
PrazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Brimonidine.
PrazosinPrazosin may increase the hypotensive activities of Brimonidine.
PrazosinBrimonidine may increase the antihypertensive activities of Prazosin.
PregabalinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Brimonidine.
PrilocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Brimonidine.
PrimidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Primidone.
PrimidonePrimidone may increase the hypotensive activities of Brimonidine.
ProcaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Procaine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Brimonidine.
ProchlorperazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brimonidine.
PromazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Promazine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Brimonidine.
PromethazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Brimonidine.
ProparacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Brimonidine.
PropofolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Propofol.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Brimonidine.
PropoxycaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Brimonidine.
PropranololPropranolol may increase the hypotensive activities of Brimonidine.
PropranololBrimonidine may increase the antihypertensive activities of Propranolol.
ProtriptylineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
ProtriptylineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Protriptyline.
PSD502Brimonidine may increase the central nervous system depressant (CNS depressant) activities of PSD502.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Brimonidine.
QuazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Brimonidine.
QuetiapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brimonidine.
QuinaprilQuinapril may increase the hypotensive activities of Brimonidine.
QuinaprilBrimonidine may increase the antihypertensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Brimonidine.
RamelteonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Brimonidine.
RamiprilRamipril may increase the hypotensive activities of Brimonidine.
RamiprilBrimonidine may increase the antihypertensive activities of Ramipril.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Brimonidine.
RemifentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brimonidine.
RemikirenRemikiren may increase the hypotensive activities of Brimonidine.
RemikirenBrimonidine may increase the antihypertensive activities of Remikiren.
RemoxiprideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brimonidine.
RescinnamineRescinnamine may increase the hypotensive activities of Brimonidine.
RescinnamineBrimonidine may increase the antihypertensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Brimonidine.
ReserpineBrimonidine may increase the antihypertensive activities of Reserpine.
RiociguatRiociguat may increase the hypotensive activities of Brimonidine.
RiociguatBrimonidine may increase the antihypertensive activities of Riociguat.
RisperidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Brimonidine.
RituximabBrimonidine may increase the hypotensive activities of Rituximab.
RomifidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Romifidine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Brimonidine.
RopiniroleBrimonidine may increase the sedative activities of Ropinirole.
RopivacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brimonidine.
RotigotineBrimonidine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Brimonidine.
S-EthylisothioureaBrimonidine may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Brimonidine.
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Brimonidine.
SaprisartanSaprisartan may increase the hypotensive activities of Brimonidine.
SaprisartanBrimonidine may increase the antihypertensive activities of Saprisartan.
ScopolamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brimonidine.
SecobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
SecobarbitalSecobarbital may increase the hypotensive activities of Brimonidine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Brimonidine.
SelexipagSelexipag may increase the hypotensive activities of Brimonidine.
SelexipagBrimonidine may increase the antihypertensive activities of Selexipag.
SertindoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sertindole.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Brimonidine.
SertralineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Sertraline.
SevofluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brimonidine.
SildenafilSildenafil may increase the antihypertensive activities of Brimonidine.
SitaxentanSitaxentan may increase the hypotensive activities of Brimonidine.
SitaxentanBrimonidine may increase the antihypertensive activities of Sitaxentan.
Sodium oxybateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Brimonidine.
SotalolThe risk or severity of adverse effects can be increased when Brimonidine is combined with Sotalol.
SpiraprilSpirapril may increase the hypotensive activities of Brimonidine.
SpiraprilBrimonidine may increase the antihypertensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Brimonidine.
StiripentolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Brimonidine.
SufentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brimonidine.
SulpirideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brimonidine.
SuvorexantBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Brimonidine.
TadalafilTadalafil may increase the antihypertensive activities of Brimonidine.
TapentadolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Brimonidine.
TasimelteonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Brimonidine.
TelmisartanTelmisartan may increase the hypotensive activities of Brimonidine.
TelmisartanBrimonidine may increase the antihypertensive activities of Telmisartan.
TemazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Brimonidine.
TemocaprilTemocapril may increase the hypotensive activities of Brimonidine.
TemocaprilBrimonidine may increase the antihypertensive activities of Temocapril.
TerazosinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Terazosin.
TerlipressinTerlipressin may increase the hypotensive activities of Brimonidine.
TerlipressinBrimonidine may increase the antihypertensive activities of Terlipressin.
TetrabenazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Brimonidine.
TetracaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Brimonidine.
TetrodotoxinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Brimonidine.
ThalidomideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Brimonidine.
ThiamylalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.
ThiamylalThiamylal may increase the hypotensive activities of Brimonidine.
ThiopentalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.
ThiopentalThiopental may increase the hypotensive activities of Brimonidine.
ThioridazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Brimonidine.
ThiothixeneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brimonidine.
TiagabineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Brimonidine.
TianeptineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Tianeptine.
TiboloneTibolone may increase the hypotensive activities of Brimonidine.
TiboloneBrimonidine may increase the antihypertensive activities of Tibolone.
TicrynafenTicrynafen may increase the hypotensive activities of Brimonidine.
TicrynafenBrimonidine may increase the antihypertensive activities of Ticrynafen.
TiletamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Brimonidine.
TimololTimolol may increase the hypotensive activities of Brimonidine.
TimololBrimonidine may increase the antihypertensive activities of Timolol.
TizanidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Brimonidine.
TolazolineTolazoline may increase the hypotensive activities of Brimonidine.
TolazolineBrimonidine may increase the antihypertensive activities of Tolazoline.
TolcaponeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brimonidine.
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Brimonidine.
TopiramateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Brimonidine.
TorasemideTorasemide may increase the hypotensive activities of Brimonidine.
TorasemideBrimonidine may increase the antihypertensive activities of Torasemide.
TramadolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Brimonidine.
TrandolaprilTrandolapril may increase the hypotensive activities of Brimonidine.
TrandolaprilBrimonidine may increase the antihypertensive activities of Trandolapril.
Trans-2-PhenylcyclopropylamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brimonidine.
TranylcypromineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brimonidine.
TravoprostTravoprost may increase the hypotensive activities of Brimonidine.
TravoprostBrimonidine may increase the antihypertensive activities of Travoprost.
TrazodoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Brimonidine.
TreprostinilTreprostinil may increase the hypotensive activities of Brimonidine.
TreprostinilBrimonidine may increase the antihypertensive activities of Treprostinil.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Brimonidine.
TriazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Brimonidine.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Brimonidine.
TrichlormethiazideBrimonidine may increase the antihypertensive activities of Trichlormethiazide.
TrifluoperazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brimonidine.
TriflupromazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brimonidine.
TrimazosinTrimazosin may increase the hypotensive activities of Brimonidine.
TrimazosinBrimonidine may increase the antihypertensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Brimonidine.
TrimethaphanBrimonidine may increase the antihypertensive activities of Trimethaphan.
TrimipramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
TrimipramineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Trimipramine.
TriprolidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Brimonidine.
UdenafilUdenafil may increase the antihypertensive activities of Brimonidine.
UnoprostoneUnoprostone may increase the hypotensive activities of Brimonidine.
UnoprostoneBrimonidine may increase the antihypertensive activities of Unoprostone.
Valproic AcidBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Brimonidine.
ValsartanValsartan may increase the hypotensive activities of Brimonidine.
ValsartanBrimonidine may increase the antihypertensive activities of Valsartan.
VardenafilVardenafil may increase the antihypertensive activities of Brimonidine.
VenlafaxineVenlafaxine may decrease the antihypertensive activities of Brimonidine.
VerapamilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Verapamil.
VigabatrinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Brimonidine.
VilazodoneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Vilazodone.
VortioxetineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Brimonidine.
XylazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Xylazine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Brimonidine.
XylometazolineXylometazoline may increase the hypotensive activities of Brimonidine.
XylometazolineBrimonidine may increase the antihypertensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Brimonidine.
ZaleplonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brimonidine.
ZiconotideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Brimonidine.
ZimelidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Zimelidine.
ZiprasidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Brimonidine.
ZolazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Brimonidine.
ZolpidemBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Brimonidine.
ZonisamideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Brimonidine.
ZopicloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Brimonidine.
ZotepineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zotepine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Brimonidine.
ZuclopenthixolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brimonidine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Rauly I, Ailhaud M, Wurch T, Pauwels PJ: alpha(2A)-adrenoceptor: G(alphai1) protein-mediated pertussis toxin-resistant attenuation of G(s) coupling to the cyclic AMP pathway. Biochem Pharmacol. 2000 Jun 15;59(12):1531-8. [PubMed:10799649 ]
  2. Wikberg-Matsson A, Simonsen U: Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55. [PubMed:11481271 ]
  3. Meana JJ, Barturen F, Garro MA, Garcia-Sevilla JA, Fontan A, Zarranz JJ: Decreased density of presynaptic alpha 2-adrenoceptors in postmortem brains of patients with Alzheimer's disease. J Neurochem. 1992 May;58(5):1896-904. [PubMed:1373179 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Trendelenburg AU, Philipp M, Meyer A, Klebroff W, Hein L, Starke K: All three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):504-12. Epub 2003 Nov 11. [PubMed:14610637 ]
  2. Bohmann C, Schollmeyer P, Rump LC: Methoxamine inhibits noradrenaline release through activation of alpha 1- and alpha 2-adrenoceptors in rat isolated kidney: involvement of purines and prostaglandins. Naunyn Schmiedebergs Arch Pharmacol. 1993 Mar;347(3):273-9. [PubMed:8097565 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Trendelenburg AU, Philipp M, Meyer A, Klebroff W, Hein L, Starke K: All three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):504-12. Epub 2003 Nov 11. [PubMed:14610637 ]
  2. Orito K, Kishi M, Imaizumi T, Nakazawa T, Hashimoto A, Mori T, Kambe T: alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator. Br J Pharmacol. 2001 Oct;134(4):763-70. [PubMed:11606316 ]
  3. Zhang W, Ordway GA: The alpha2C-adrenoceptor modulates GABA release in mouse striatum. Brain Res Mol Brain Res. 2003 Apr 10;112(1-2):24-32. [PubMed:12670699 ]
  4. Prinster SC, Holmqvist TG, Hall RA: Alpha2C-adrenergic receptors exhibit enhanced surface expression and signaling upon association with beta2-adrenergic receptors. J Pharmacol Exp Ther. 2006 Sep;318(3):974-81. Epub 2006 Jun 6. [PubMed:16757535 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xanthine dehydrogenase activity
Specific Function:
Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal, and vanillin. Plays a key role in the metabolism of xenobiotics and drugs containing aromatic azaheterocyclic substituents. Participates in the bioactivation of prodrugs such as famciclovir, catalyz...
Gene Name:
AOX1
Uniprot ID:
Q06278
Molecular Weight:
147916.735 Da
References
  1. Acheampong AA, Chien DS, Lam S, Vekich S, Breau A, Usansky J, Harcourt D, Munk SA, Nguyen H, Garst M, Tang-Liu D: Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica. 1996 Oct;26(10):1035-55. [PubMed:8905918 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 03:39